Ankylosing Spondylitis (AS) is an autoimmune disease characterized by inflammation
of the spine and sacroiliac joints, historically described in young males with progressive
structural damage of the spine, and later used as model to identify a group of inflammatory
diseases known as Spondyloarthritis (SpA) [
[1]
]. AS is currently considered the advanced stage of Axial Spondyloarthritis (axSpA),
when chronic joint inflammation has progressed to erosions and ankylosis, features
that are detectable be means of conventional radiology (x-rays) and therefore defined
as radiographic axial spondyloarthritis (r-axSpA)1 [
[2]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Ankylosing Spondylitis and Axial Spondyloarthritis.N Engl J Med. 2016; 374: 2563-2574
- Axial spondyloarthritis.Lancet. 2017; 390: 73-84
- Ankylosing Spondylitis and Axial Spondyloarthritis.N Engl J Med. 2016; 375: 1302-1303
- Axial spondyloarthritis.Ann Rheum Dis. 2021; 80: 1511-1521
- Imaging in axial spondyloarthritis: diagnostic problems and pitfalls.Rheum Dis Clin North Am. 2012; 38: 513-522
López-Medina C., Ramiro S., van der Heijde D., Sieper J., Dougados M., Molto A.. Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2).
- Understanding the paradigm of non-radiographic axial spondyloarthritis.Clin Rheumatol. 2021; 40: 501-512
- 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.Arthritis Rheumatol. 2019; 71: 1599-1613
- 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.Ann Rheum Dis. 2017; 76: 978-991
- Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review.RMD Open. 2017; 3e000524
- Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?.Clin Exp Rheumatol. 2021; 39 Suppl 129: S129-S134
- Current and future status of JAK inhibitors.Lancet. 2021; 398: 803-816
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.Rheumatology (Oxford). 2019; 58 (Suppl): i43-i54
- JAK Inhibitors for Axial Spondyloarthritis: what does the Future Hold?.Curr Rheumatol Rep. 2021; 23
- In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).BMC Rheumatol. 2018; 2: 23
- JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.Ann Rheum Dis. 2021; 80: 865-875
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.N Engl J Med. 2022; 386: 316-326
Kragstrup T.W., Glintborg B., Svensson A.L., et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1).
- Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis — Past, Present, and Future.N Engl J Med. 2022; 386: 387-389
- Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis.Eur J Internal Med. 2022; 102: 45-51
Article info
Publication history
Published online: May 20, 2022
Accepted:
May 16,
2022
Received:
May 10,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
